Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LY 3875383

Next Previous
Drug Profile

LY 3875383

Alternative Names: LY-3875383

Latest Information Update: 24 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antihyperlipidaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hypertriglyceridaemia

Most Recent Events

  • 14 Nov 2022 Phase-I clinical trials in Hypertriglyceridaemia (In the elderly, In adults) in Singapore (SC) (NCT05609825; 18537; J4D-MC-EZFA)
  • 08 Nov 2022 Eli Lilly and Company plans a phase I trial for Hypertriglyceridemia in USA and Singapore (NCT05609825)
  • 08 Nov 2022 Preclinical trials in Hypertriglyceridaemia in Singapore, USA (SC) prior to November 2022 (NCT05609825)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top